MLYS Stock Summary and Trading Ideas (Mineralys Therapeutics | NASDAQ:MLYS)

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Mineralys Therapeutics trades on the NASDAQ stock market under the symbol MLYS.

As of October 29, 2026, MLYS stock price declined to $21.24 with 1,914,125 million shares trading.

MLYS has a beta of 2.05, meaning it tends to be more sensitive to market movements. MLYS has a correlation of 0.22 to the broad based SPY ETF.

MLYS has a market cap of $1.88 billion. This is considered a Small Cap stock.

In the last 3 years, MLYS traded as high as $47.65 and as low as $5.85.

The top ETF exchange traded funds that MLYS belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

MLYS has underperformed the market in the last year with a return of -47.8%, while the SPY ETF gained +13.1%. In the last 3 month period, MLYS fell short of the market, returning -21.2%, while SPY returned +4.1%. However, in the most recent 2 weeks MLYS has outperformed the stock market by returning +2.3%, while SPY returned 0.0%.

MLYS support price is $20.58 and resistance is $22.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MLYS shares will trade within this expected range on the day.